Literature DB >> 8455682

Improved renal function in children with cystinosis treated with cysteamine.

T C Markello1, I M Bernardini, W A Gahl.   

Abstract

BACKGROUND: The lysosomal storage disease cystinosis results in renal failure at approximately 10 years of age. Although oral cysteamine therapy is recognized to preserve kidney function, the extent of renal benefit has not been determined.
METHODS: Between 1960 and 1992, we determined 24-hour creatinine clearances in 76 children with cystinosis during 1081 admissions to the National Institutes of Health. Seventeen children were considered to have received adequate treatment with cysteamine, since they had depletion of cystine from leukocytes and began therapy before the age of 2 years; treatment lasted a mean of 7.1 years. Thirty-two children were considered to have received partial treatment, since they had poor compliance with therapy or began treatment after the age of 2; treatment lasted a mean of 4.5 years. Twenty-seven children were followed in the era before cysteamine therapy and thus never received cysteamine.
RESULTS: Of the 27 children who never received cysteamine, 16 were followed at the National Institutes of Health until renal failure occurred; their mean (+/- SD) creatinine clearance was 8.0 +/- 4.8 ml per minute per 1.73 m2 of body-surface area at a mean age of 8.3 +/- 1.9 years. Of the 17 children who received adequate treatment, none had renal failure; their mean creatinine clearance was 57 +/- 20 ml per minute per 1.73 m2 at 8.3 +/- 3.8 years of age. The mean creatinine clearance of the children who received partial or adequate treatment with cysteamine increased with age up to the age of five years and then declined linearly with age at a normal rate. For the children who received adequate treatment, the mean creatinine clearance was predicted to reach 0 ml per minute per 1.73 m2 at the age of 74 years, as compared with 20 years of age for the children who received partial treatment. With no therapy, the mean creatinine clearance reaches 0 ml per minute per 1.73 m2 at 10 years of age.
CONCLUSIONS: Children with cystinosis who are treated early and adequately with cysteamine have renal function that increases during the first five years of life and then declines at a normal rate. Patients with poorer compliance and those who are treated at an older age do less well.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8455682     DOI: 10.1056/NEJM199304223281604

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  80 in total

1.  Evaluation of topical cysteamine therapy in the CTNS(-/-) knockout mouse using in vivo confocal microscopy.

Authors:  Jennifer L Simpson; Chyong Jy Nien; Kevin J Flynn; James V Jester
Journal:  Mol Vis       Date:  2011-10-08       Impact factor: 2.367

2.  First Successful Conception Induced by a Male Cystinosis Patient.

Authors:  Koenraad R Veys; Kathleen W D'Hauwers; Angelique J C M van Dongen; Mirian C Janssen; Martine T P Besouw; Ellen Goossens; Lambert P van den Heuvel; Alex A M M Wetzels; Elena N Levtchenko
Journal:  JIMD Rep       Date:  2017-04-13

3.  Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion.

Authors:  Meredith C Fidler; Bruce A Barshop; Jon A Gangoiti; Reena Deutsch; Michael Martin; Jerry A Schneider; Ranjan Dohil
Journal:  Br J Clin Pharmacol       Date:  2007-01       Impact factor: 4.335

4.  The battlefield of rare diseases: where uncommon insights are common.

Authors:  William A Gahl
Journal:  Sci Transl Med       Date:  2012-10-03       Impact factor: 17.956

5.  Inflammasome activation by cystine crystals: implications for the pathogenesis of cystinosis.

Authors:  Giusi Prencipe; Ivan Caiello; Stephanie Cherqui; Thomas Whisenant; Stefania Petrini; Francesco Emma; Fabrizio De Benedetti
Journal:  J Am Soc Nephrol       Date:  2014-02-13       Impact factor: 10.121

Review 6.  Lysosome dysfunction in the pathogenesis of kidney diseases.

Authors:  Kameswaran Surendran; Seasson P Vitiello; David A Pearce
Journal:  Pediatr Nephrol       Date:  2013-11-12       Impact factor: 3.714

7.  Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells.

Authors:  A Bergamini; M Capozzi; L Ghibelli; L Dini; A Salanitro; G Milanese; T Wagner; S Beninati; C D Pesce; C Amici
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

Review 8.  Skeletal implications and management of cystinosis: three case reports and literature review.

Authors:  Justine Bacchetta; Marcella Greco; Aurélia Bertholet-Thomas; François Nobili; Jozef Zustin; Pierre Cochat; Francesco Emma; Georges Boivin
Journal:  Bonekey Rep       Date:  2016-08-17

9.  CTNS mutations in an American-based population of cystinosis patients.

Authors:  V Shotelersuk; D Larson; Y Anikster; G McDowell; R Lemons; I Bernardini; J Guo; J Thoene; W A Gahl
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

10.  High-resolution mapping of the gene for cystinosis, using combined biochemical and linkage analysis.

Authors:  G Jean; A Fuchshuber; M M Town; O Gribouval; J A Schneider; M Broyer; W van't Hoff; P Niaudet; C Antignac
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.